Thomas E. Pennington

1.3k total citations
41 papers, 263 citations indexed

About

Thomas E. Pennington is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Thomas E. Pennington has authored 41 papers receiving a total of 263 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 12 papers in Molecular Biology and 6 papers in Epidemiology. Recurrent topics in Thomas E. Pennington's work include Cutaneous Melanoma Detection and Management (29 papers), CAR-T cell therapy research (13 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Thomas E. Pennington is often cited by papers focused on Cutaneous Melanoma Detection and Management (29 papers), CAR-T cell therapy research (13 papers) and Cancer Immunotherapy and Biomarkers (12 papers). Thomas E. Pennington collaborates with scholars based in Australia, Netherlands and United Kingdom. Thomas E. Pennington's co-authors include Craig A. Hutton, Georgina V. Long, Alexander M. Menzies, Andrew J. Spillane, Richard A. Scolyer, Kerwin F. Shannon, Robyn P.M. Saw, Matteo S. Carlino, W. Martin C. Klop and Christian U. Blank and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

Thomas E. Pennington

31 papers receiving 263 citations

Peers

Thomas E. Pennington
Giuseppina Rea Italy
Feifei Gu China
Samuel H. Myers Italy
M. Tamura Japan
Cristina Valero Spain
Gemma Azaceta Spain
Yugandhar Beesetty United States
Hongying Zheng China
Giuseppina Rea Italy
Thomas E. Pennington
Citations per year, relative to Thomas E. Pennington Thomas E. Pennington (= 1×) peers Giuseppina Rea

Countries citing papers authored by Thomas E. Pennington

Since Specialization
Citations

This map shows the geographic impact of Thomas E. Pennington's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Pennington with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Pennington more than expected).

Fields of papers citing papers by Thomas E. Pennington

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas E. Pennington. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Pennington. The network helps show where Thomas E. Pennington may publish in the future.

Co-authorship network of co-authors of Thomas E. Pennington

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas E. Pennington. A scholar is included among the top collaborators of Thomas E. Pennington based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas E. Pennington. Thomas E. Pennington is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Thompson, John F., Roger F. Uren, Kevin London, et al.. (2025). Nodal radioactivity after lymphoscintigraphy as a guide to sentinel node–positivity in melanoma patients. European Journal of Surgical Oncology. 51(9). 110225–110225.
2.
Liu, Wendy, et al.. (2025). Approaches to Surgical Management of Anorectal Melanoma in the Pre- and Post-Immunotherapy Eras. Diseases of the Colon & Rectum. 68(6). 746–752.
3.
4.
5.
Zhou, Li, Edward Hsiao, Serigne Lo, et al.. (2024). FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma.. Journal of Clinical Oncology. 42(16_suppl). 9523–9523.
6.
7.
Ch’ng, Sydney, Jonathan R. Stretch, Robyn P.M. Saw, et al.. (2024). Impact of an Online Risk Calculator for Sentinel Node Positivity on Management of Patients with T1 and T2 Melanomas. Annals of Surgical Oncology. 31(8). 5331–5339. 2 indexed citations
8.
Pennington, Thomas E., John F. Thompson, & Alexander H. R. Varey. (2024). ASO Author Reflections: Is Sentinel Node Biopsy Still of Value for Patients with High-Risk Primary Melanomas Eligible for Adjuvant Immunotherapy?. Annals of Surgical Oncology. 32(6). 4225–4226.
9.
Gonzalez, Maria, Alexander Christopher Jonathan Van Akkooi, Sydney Ch’ng, et al.. (2024). A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC).. Journal of Clinical Oncology. 42(16_suppl). TPS9613–TPS9613.
10.
Reijers, Irene L. M., Petros Dimitriadis, Alexander M. Menzies, et al.. (2023). 1095P Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma. Annals of Oncology. 34. S660–S660. 2 indexed citations
11.
Wells, Adrian, Georgina V. Long, Richard A. Scolyer, et al.. (2022). Successful Manufacturing of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy from Cryopreserved Melanoma Tumors Shipped from Australia. Transplantation and Cellular Therapy. 28(3). S226–S227. 1 indexed citations
12.
Scolyer, Richard A., Carla H. van Gils, Sydney Ch’ng, et al.. (2022). Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes. European Journal of Cancer. 167. 123–132. 8 indexed citations
13.
Scolyer, Richard A., Carla H. van Gils, Sydney Ch’ng, et al.. (2022). Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients. European Journal of Cancer. 167. 133–141. 5 indexed citations
14.
Pennington, Thomas E., Cathy Zhao, Andrew J. Colebatch, et al.. (2022). Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma. Australasian Journal of Dermatology. 63(2). e133–e137. 1 indexed citations
15.
Long, Georgina V., Andrew J. Spillane, Thomas E. Pennington, et al.. (2022). 793P NeoPeLe: A phase II trial of neoadjuvant (NAT) pembrolizumab (Pembro) combined with lenvatinib (Lenva) in resectable stage III melanoma. Annals of Oncology. 33. S906–S907. 11 indexed citations
16.
Ch’ng, Sydney, Semra Uyulmaz, Matteo S. Carlino, et al.. (2021). Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. European Journal of Cancer. 153. 8–15. 5 indexed citations
17.
Pennington, Thomas E., et al.. (2020). Perianal extramammary Paget's disease: a diagnosis worth considering. ANZ Journal of Surgery. 90(11). E135–E136.
18.
Pennington, Thomas E., May Myo Thwin, Mark Sywak, Leigh Delbridge, & Stan B. Sidhu. (2018). Sonographic Volumetric Assessment Is a More Accurate Measure Than Maximum Diameter Alone in Papillary Thyroid Cancer. Journal of the Endocrine Society. 2(11). 1284–1292. 5 indexed citations
19.
Kruijff, Schelto, Ahmad Aniss, Thomas E. Pennington, et al.. (2015). Oxyphil Cell Parathyroid Adenomas Causing Primary Hyperparathyroidism: a Clinico-Pathological Correlation. Endocrine Pathology. 26(3). 250–254. 17 indexed citations
20.
Axford, John S., Allen C. Steere, Klaus Hansen, et al.. (1993). 2nd European Symposium on Lyme Borreliosis. A NATO advanced research workshop. United Kingdom, 19-20 May 1993. Abstracts.. Annals of the Rheumatic Diseases. 52(5). 387–412. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giuseppina Rea Breakdown of academic impact, for papers by Feifei Gu Breakdown of academic impact, for papers by Samuel H. Myers Breakdown of academic impact, for papers by M. Tamura Breakdown of academic impact, for papers by Cristina Valero Breakdown of academic impact, for papers by Gemma Azaceta Breakdown of academic impact, for papers by Yugandhar Beesetty Breakdown of academic impact, for papers by Hongying Zheng
Rankless by CCL
2026